[1. Sanchis -Gomar F, Perez -Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016;4(13):256.10.21037/atm.2016.06.33]Search in Google Scholar
[2. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocar-dial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454-71.10.1016/j.jacc.2015.02.032]Search in Google Scholar
[3. Headrick JP, Ashton KJ, Rose’meyer RB, Peart JN. Cardiovascular adeno-sine receptors: expression, actions and interactions. Pharmacol Ther 2013;140(1):92-111.10.1016/j.pharmthera.2013.06.002]Search in Google Scholar
[4. Burnstock G, Pelleg A. Cardiac purinergic signalling in health and disease. Purinergic Signal 2015;11(1):1-46.10.1007/s11302-014-9436-1]Search in Google Scholar
[5. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.]Search in Google Scholar
[6. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/Reperfusion. Compr Physiol 2016;7(1):113-70.10.1002/cphy.c160006]Search in Google Scholar
[7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124-36.10.1161/01.CIR.74.5.1124]Search in Google Scholar
[8. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116(2):173-91.10.1016/j.pharmthera.2007.06.005]Search in Google Scholar
[9. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285(2):H579-88.10.1152/ajpheart.01064.2002]Search in Google Scholar
[10. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre -, post-, and remote conditioning. Circ Res 2015;116(4):674-99.10.1161/CIRCRESAHA.116.305348]Search in Google Scholar
[11. Ely SW, Mentzer RM Jr, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985;90(4):549-56.10.1016/S0022-5223(19)38568-X]Search in Google Scholar
[12. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991;84(1):350-6.10.1161/01.CIR.84.1.350]Search in Google Scholar
[13. Schlack W, Schäfer M, Uebing A, Schäfer S, Borchard U, Thämer V. Aden-osine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 1993;22(1):89-96.10.1097/00005344-199307000-00015]Search in Google Scholar
[14. Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28(7):1057-61.10.1093/cvr/28.7.1057]Search in Google Scholar
[15. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1 -selective adenosine analogues protects the heart against infarction. Circulation 1992;85(2):659-65.10.1161/01.CIR.85.2.659]Search in Google Scholar
[16. Louttit JB, Hunt AA, Maxwell MP, Drew GM. The time course of cardio-protection induced by GR79236, a selective adenosine A1 -receptor agonist, in myocardial ischaemia -reperfusion injury in the pig. J Cardiovasc Pharmacol 1999;33(2):285-91.10.1097/00005344-199902000-00016]Search in Google Scholar
[17. Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, et al. Selective activation of A3 adenosine receptors with N6 -(3 -iodobenzyl) adenosine -5’ -N -methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80(6):800-9.10.1161/01.RES.80.6.800]Search in Google Scholar
[18. Carr CS, Hill RJ, Masamune H, Kennedy SP, Knight DR, Tracey WR, et al. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 1997;36(1):52-9.10.1016/S0008-6363(97)00160-0]Search in Google Scholar
[19. Tracey WR, Magee W, Masamune H, Kennedy SP, Knight DR, Buchholz RA, et al. Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33(2):410-5.10.1016/S0008-6363(96)00240-4]Search in Google Scholar
[20. Thourani VH, Nakamura M, Ronson RS, Jordan JE, Zhao ZQ, Levy JH, et al. Adenosine A3 -receptor stimulation attenuates postischemic dysfunction through KATP channels. Am J Physiol 1999;277(1):H228-35.10.1152/ajpheart.1999.277.1.H22810409201]Search in Google Scholar
[21. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia -reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 2003;285(2):H607-13.10.1152/ajpheart.01001.2002386082212689858]Search in Google Scholar
[22. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Novel N6-substituted adenosine 5’ -N -methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 2003;285(6):H2780-7.10.1152/ajpheart.00411.200312919933]Search in Google Scholar
[23. Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, et al. Cl -IB--MECA [2 -chloro -N6 -(3 -iodobenzyl)adenosine -5’ -N -methylcarboxamid] reduces ischemia/reperfusion injury in mice by activating the A3 adeno-sine receptor. J Pharmacol Exp Ther 2006;319(3):1200-10.10.1124/jpet.106.11135116985166]Search in Google Scholar
[24. Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, et al. The A3 adenosine receptor agonist CP -532,903 [N6 -(2,5 -dichlorobenzyl) -3’- -aminoadenosine -5’ -N -methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP -sensitive potassium channel. J Pharmacol Exp Ther 2008;324(1):234-43.10.1124/jpet.107.127480]Search in Google Scholar
[25. Norton ED, Jackson EK, Turner MB, Virmani R, Forman MB. The effects of intravenous infusions of selective adenosine A1 -receptor and A2 -receptor agonists on myocardial reperfusion injury. Am Heart J 1992;123(2):332-8.10.1016/0002-8703(92)90643-A]Search in Google Scholar
[26. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J. A3 adenosine receptor activation attenuates neutrophil function and neutrophil -mediated reperfusion injury. Am J Physiol 1999;277(5):H1895-905.10.1152/ajpheart.1999.277.5.H189510564145]Search in Google Scholar
[27. Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA. A3 adeno-sine receptor activation during reperfusion reduces infarct size through actions on bone marrow -derived cells. J Mol Cell Cardiol 2010;49(2):280-6.10.1016/j.yjmcc.2010.01.018288551620132822]Search in Google Scholar
[28. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten -Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280(1):301-9.]Search in Google Scholar
[29. Lasley RD, Jahania MS, Mentzer RM Jr. Beneficial effects of adenosine A2a agonist CGS -21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001;280(4):H1660-6.10.1152/ajpheart.2001.280.4.H166011247777]Search in Google Scholar
[30. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C -adenosine A2b receptor cascade. Cardiovasc Res 2006;70(2):308-14.10.1016/j.cardiores.2006.02.01416545350]Search in Google Scholar
[31. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, et al. Myocardial infarct -sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006;114(19):2056-64.10.1161/CIRCULATIONAHA.106.64924417060376]Search in Google Scholar
[32. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, Linden J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 2008;295(5):H1825-33.10.1152/ajpheart.495.2008261458918757481]Search in Google Scholar
[33. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009;47(5):684-90.10.1016/j.yjmcc.2009.08.009278274419695259]Search in Google Scholar
[34. Methner C, Schmidt K, Cohen MV, Downey JM, Krieg T. Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 2010;299(4):H1262-4.10.1152/ajpheart.00181.2010295735120709859]Search in Google Scholar
[35. Urmaliya VB, Church JE, Coupar IM, Rose’Meyer RB, Pouton CW, White PJ. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. J Cardiovasc Pharmacol 2009;53(5):424-33.10.1097/FJC.0b013e3181a443e219333129]Search in Google Scholar
[36. Urmaliya VB, Pouton CW, Ledent C, Short JL, White PJ. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia -reperfused isolated mouse heart. J Cardiovasc Pharmacol 2010;56(4):379-88.10.1097/FJC.0b013e3181f03d0520930592]Search in Google Scholar
[37. Zhan E, McIntosh VJ, Lasley RD. Adenosine A2A and A2B receptors are both required for adenosine A1 receptor -mediated cardioprotection. Am J Physiol Heart Circ Physiol 2011;301(3):H1183-9.10.1152/ajpheart.00264.2011319108021743001]Search in Google Scholar
[38. Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Adenosine A3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX. Am J Physiol Heart Circ Physiol 2001;281(2):H847-53.10.1152/ajpheart.2001.281.2.H84711454590]Search in Google Scholar
[39. Tian Y, Marshall M, French BA, Linden J, Yang Z. The infarct -sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A2A receptors. Basic Res Cardiol 2015;110(2):16.10.1007/s00395-015-0473-x25711314]Search in Google Scholar
[40. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, et al. Aden-osine A1 agonist at reperfusion trial (AART): results of a three -center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14(6):607-14.10.1023/A:1007850527878]Search in Google Scholar
[41. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol 2016;13(4):193-209.10.1038/nrcardio.2016.5]Search in Google Scholar
[42. Wang J, Drake L, Sajjadi F, Firestein GS, Mullane KM, Bullough DA. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320(2-3):241-8.10.1016/S0014-2999(96)00901-6]Search in Google Scholar
[43. Hill RJ, Oleynek JJ, Magee W, Knight DR, Tracey WR. Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol 1998;30(3):579-85.10.1006/jmcc.1997.06219515033]Search in Google Scholar
[44. Armstrong S, Ganote CE. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A3 receptor involvement. Cardiovasc Res 1994;28(7):1049-56.10.1093/cvr/28.7.10497525060]Search in Google Scholar
[45. Kuno A, Critz SD, Cui L, Solodushko V, Yang XM, Krahn T, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b -dependent signaling during early reperfusion. J Mol Cell Cardiol 2007;43(3):262-71.10.1016/j.yjmcc.2007.05.016272954717632123]Search in Google Scholar
[46. Kuno A, Solenkova NV, Solodushko V, Dost T, Liu Y, Yang XM, et al. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008;295(3):H1288-95.10.1152/ajpheart.00209.2008254447918660452]Search in Google Scholar
[47. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6 -(3 -iodobenzyl) -adenosine-5’ -N -methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3β. J Pharmacol Exp Ther 2006;318(1): 124-31.10.1124/jpet.106.10147716611852]Search in Google Scholar
[48. Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, et al. A1 or A3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res 2001;88(5):520-8.10.1161/01.RES.88.5.52011249876]Search in Google Scholar
[49. Zhao TC, Kukreja RC. Late preconditioning elicited by activation of aden-osine A3 receptor in heart: role of NF -κB, iNOS and mitochondrial KATP channel. J Mol Cell Cardiol 2002;34(3):263-77.10.1006/jmcc.2001.151011945020]Search in Google Scholar
[50. Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A1 receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase - and protein kinase C -dependent mechanism. Circ Res 2000;86(9):989-97.10.1161/01.RES.86.9.98910807872]Search in Google Scholar
[51. Sarkar K, Cai Z, Gupta R, Parajuli N, Fox -Talbot K, Darshan MS, et al. Hypoxia -inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci U S A 2012;109(26):10504-9.10.1073/pnas.1208314109338709022699503]Search in Google Scholar
[52. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med 2013;19(6):345-54.10.1016/j.molmed.2013.02.005367412623540714]Search in Google Scholar
[53. Reid EA, Kristo G, Yoshimura Y, Ballard -Croft C, Keith BJ, Mentzer RM Jr, et al. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling. Am J Physiol Heart Circ Physiol 2005;288(5):H2253-9.10.1152/ajpheart.01009.2004]Search in Google Scholar
[54. Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C, et al. Adora2b signaling on bone marrow derived cells dampens myocardial ischemia -reperfusion injury. Anesthesiology 2012;116(6): 1245-57.10.1097/ALN.0b013e318255793c]Search in Google Scholar
[55. Su Q, Nyi TS, Li L. Adenosine and verapamil for no -reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2015;(5):CD009503.10.1002/14651858.CD009503.pub3]Search in Google Scholar
[56. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24(2):116-47.10.1111/j.1527-3466.2006.00116.x]Search in Google Scholar
[57. Kassimis G, Davlouros P, Patel N, De Maria G, Kallistratos MS, Kharbanda RK, et al. Adenosine as an adjunct therapy in ST elevation myocardial infarction patients: myth or truth? Cardiovasc Drugs Ther 2015;29(5): 481-93.]Search in Google Scholar
[58. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocar-dial infarction: results of a multicenter, randomized, placebo -controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34(6):1711-20.10.1016/S0735-1097(99)00418-0]Search in Google Scholar
[59. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Investigators. A randomized, double -blinded, placebo -controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD -II). J Am Coll Cardiol 2005;45(11):1775-80.10.1016/j.jacc.2005.02.06115936605]Search in Google Scholar
[60. Cohen MV, Downey JM. AMISTAD trials: possible reasons for lack of success. J Am Coll Cardiol 2006;47(6):1226-38.]Search in Google Scholar
[61. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, et al. Improvement in microvascular reflow and reduction of infarct size with adeno-sine in patients undergoing primary coronary stenting. Am J Cardiol 2005;96(10):1410-5.10.1016/j.amjcard.2005.06.09016275189]Search in Google Scholar
[62. Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2012;125(10):1713-9.]Search in Google Scholar
[63. Gao Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A PRISMA -compliant meta -analysis. Medicine (Baltimore) 2015;94(32):e1279.10.1097/MD.0000000000001279461669026266362]Search in Google Scholar
[64. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoro-nary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101(18):2154-9.10.1161/01.CIR.101.18.2154]Search in Google Scholar
[65. Grygier M, Araszkiewicz A, Lesiak M, Janus M, Kowal J, Skorupski W, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2011;107(8):1131-5.10.1016/j.amjcard.2010.12.01021310372]Search in Google Scholar
[66. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, et al. High -dose intracoronary adenosine for myocardial salvage in patients with acute ST -segment elevation myocardial infarction. Eur Heart J 2011;32(7):867-77.10.1093/eurheartj/ehq49221196444]Search in Google Scholar
[67. Garcia -Dorado D, García -del -Blanco B, Otaegui I, Rodríguez -Palomares J, Pineda V, Gimeno F, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol 2014;177(3):935-41.10.1016/j.ijcard.2014.09.20325449504]Search in Google Scholar
[68. Singh M, Shah T, Khosla K, Singh P, Molnar J, Khosla S, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta -analysis of randomized controlled trials. Ther Adv Cardiovasc Dis 2012;6(3):101-14.10.1177/175394471244667022562999]Search in Google Scholar
[69. Polimeni A, De Rosa S, Sabatino J, Sorrentino S, Indolfi C. Impact of intra-coronary adenosine administration during primary PCI: A meta -analysis. Int J Cardiol 2016;203:1032-41.10.1016/j.ijcard.2015.11.08626630632]Search in Google Scholar
[70. Nazir SA, Khan JN, Mahmoud IZ, Greenwood JP, Blackman DJ, Kunadian V, et al. The REFLO -STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST -Elevation Myocardial Infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Southampton (UK): NIHR Journals Library; 2016. Efficacy and Mechanism Evaluation.10.3310/eme0309027929619]Search in Google Scholar
[71. Bulluck H, Sirker A, Loke YK, Garcia -Dorado D, Hausenloy DJ. Clinical benefit of adenosine as an adjunct to reperfusion in ST -elevation myocardial infarction patients: An updated meta -analysis of randomized controlled trials. Int J Cardiol 2016;202:228-37.10.1016/j.ijcard.2015.09.005466930526402450]Search in Google Scholar
[72. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017;38(11):774-84.]Search in Google Scholar